STOCK TITAN

Ligand (NASDAQ: LGND) director exercises options, sells 2,161 common shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Director John L. LaMattina of LIGAND PHARMACEUTICALS INC exercised stock options and sold the resulting shares. He exercised a non-qualified stock option for 2,161 shares of common stock at an exercise price of $114.15 per share, then sold 2,161 shares of common stock in an open-market transaction at $200.76 per share on the same day. Following these transactions, he directly holds 30,724 shares of Ligand common stock. The option position associated with these 2,161 shares is now fully exercised.

Positive

  • None.

Negative

  • None.
Insider LAMATTINA JOHN L
Role Director
Sold 2,161 shs ($434K)
Type Security Shares Price Value
Exercise Non-Qualified Stock Option (right to buy) 2,161 $0.00 --
Exercise Common Stock 2,161 $114.15 $247K
Sale Common Stock 2,161 $200.76 $434K
Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 0 shares (Direct); Common Stock — 32,885 shares (Direct)
Footnotes (1)
  1. [object Object]
Options exercised 2,161 shares Non-qualified stock option exercised March 6, 2026
Exercise price $114.15 per share Strike price for 2,161-share option
Shares sold 2,161 shares Open-market sale on March 6, 2026
Sale price $200.76 per share Price received for common stock sale
Shares owned after transaction 30,724 shares Direct Ligand common stock holdings post-trade
Non-Qualified Stock Option financial
"security_title: "Non-Qualified Stock Option (right to buy)""
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
exercise price financial
"at an exercise price of $195.91 per share, but was adjusted"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
separation financial
"adjusted pursuant to the OmniAb Inc. separation from the issuer"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LAMATTINA JOHN L

(Last)(First)(Middle)
555 HERITAGE DRIVE
SUITE 200

(Street)
JUPITER FLORIDA 33458

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
LIGAND PHARMACEUTICALS INC [ LGND ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/06/2026M2,161A$114.1532,885D
Common Stock03/06/2026S2,161D$200.7630,724D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy)$114.1503/06/2026M2,161 (1)06/19/2028Common Stock2,161$00D
Explanation of Responses:
1. This Option was previously reported as a Grant of 2,474 shares, which vested in full on June 6, 2019, at an exercise price of $195.91 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
By: /s/ Andrew Reardon, Attorney-in-Fact For John L. LaMattina03/31/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Ligand (LGND) director John L. LaMattina report in this Form 4?

John L. LaMattina exercised stock options for 2,161 Ligand shares and sold 2,161 common shares in an open-market transaction. These trades reflect an exercise-and-sell sequence on the same day, updating his direct ownership position in Ligand stock.

How many Ligand (LGND) shares did John L. LaMattina sell and at what price?

He sold 2,161 shares of Ligand common stock at $200.76 per share in an open-market transaction. This sale followed an option exercise for the same number of shares, converting a derivative position into common stock before selling.

What options did John L. LaMattina exercise in the latest Ligand (LGND) filing?

He exercised a non-qualified stock option covering 2,161 shares of Ligand common stock at an exercise price of $114.15 per share. The option, originally granted in 2019 and later adjusted after the OmniAb separation, is now fully exercised.

How many Ligand (LGND) shares does John L. LaMattina own after these transactions?

After exercising options and selling 2,161 shares, John L. LaMattina directly owns 30,724 shares of Ligand common stock. This figure reflects his updated direct holdings as reported following the March 6, 2026 transactions.

Was the Ligand (LGND) option grant to John L. LaMattina previously adjusted?

Yes. The option was originally reported as a grant of 2,474 shares vesting June 6, 2019 at a $195.91 exercise price, but it was later adjusted in connection with the separation of OmniAb Inc. from Ligand, as disclosed in the footnote.